Comparative study of the biological characteristics of two human ovarian carcinoma models in nude mice

Comparative study of the biological characteristics of two human ovarian carcinoma models in nude mice
复制标题

两种人卵巢癌裸鼠模型生物学特性的比较研究

DOI:
--
复制
发表时间:
2011
期刊:
重庆医科大学报
影响因子:
--
通讯作者:
Sun Jiang Chuan
Sun Jiang Chuan
中科院分区:
其他
文献类型:
--
作者:
Zhu Yi;Liu Hong Xia;Pu Cai Xiu;Chen Jia;Chang Shu Fang;Sun Jiang Chuan

文献摘要

相似文献

目的:建立人卵巢癌裸鼠腹腔注射(IP)和皮下注射(SC)模型,比较两种模型的生物学特性。方法:将A2780/DDP细胞悬液分别腹腔注射和皮下注射建立人卵巢癌裸鼠模型,观察其生长行为和生物学特性,流式细胞术(FCM)分析细胞周期分布,免疫组化法检测LHRH-R的表达。成功建立人卵巢癌模型,两组移植成功率均为100% IP组和SC组的中位生存期分别为30.000±1.095天和41.000±0.894天,流式细胞仪分析显示,两组移植瘤细胞周期分布与A2780/结论:人卵巢癌裸鼠移植瘤模型易于建立,IP模型能模拟人卵巢癌患者腹腔内的消退行为,是卵巢癌治疗研究的理想模型。
Objective:To establish intraperitoneal(IP) injection model and subcutaneous(SC) injection model of human ovarian carcinoma in nude mice and compare their biological characteristics.Methods:The cell suspension derived from A2780/DDP were injected intraperitoneally or subcutaneously in nude mice to establish human epithelial ovarian carcinoma models,and their growth behavior and biological characteristics were observed.Distribution of cell cycles were analyzed by flow cytometry(FCM).Expression of LHRH-R were investigated by immunohistochemistry.Results:The human ovarian carcinoma models were established successfully.The success rate of transplantation in both groups were 100%.The median survival time lengths in IP group and SC group were 30.000±1.095 days and 41.000±0.894 days,respectively.FCM analysis showed the distribution of cell cycles of xenografted tumors in two groups were the same as those of A2780/DDP cells.Histology and electron microscopy showed the same characteristics and morphological properties in the two groups,and immunohistochemistry staining of LHRH-R were both positive.Conclusion:Human ovarian carcinoma models in nude mice are easy to establish.And the IP model may be an ideal model for treatment research of ovarian carcinoma as it simulates the intraperitoneally dessiminating behavior of human ovarian carcinoma in the patients.